Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen; Deal Valued Up to EUR695M

Micromet, Inc. MITI announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, to be selected by Amgen.